207 related articles for article (PubMed ID: 31358539)
1. Characterization and Comparison of GITR Expression in Solid Tumors.
Vence L; Bucktrout SL; Fernandez Curbelo I; Blando J; Smith BM; Mahne AE; Lin JC; Park T; Pascua E; Sai T; Chaparro-Riggers J; Subudhi SK; Scutti JB; Higa MG; Zhao H; Yadav SS; Maitra A; Wistuba II; Allison JP; Sharma P
Clin Cancer Res; 2019 Nov; 25(21):6501-6510. PubMed ID: 31358539
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
[TBL] [Abstract][Full Text] [Related]
3. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
4. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
5. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
[TBL] [Abstract][Full Text] [Related]
7. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Avogadri F; Zappasodi R; Yang A; Budhu S; Malandro N; Hirschhorn-Cymerman D; Tiwari S; Maughan MF; Olmsted R; Wolchok JD; Merghoub T
Cancer Immunol Res; 2014 May; 2(5):448-58. PubMed ID: 24795357
[TBL] [Abstract][Full Text] [Related]
8. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation.
Xiao X; Shi X; Fan Y; Zhang X; Wu M; Lan P; Minze L; Fu YX; Ghobrial RM; Liu W; Li XC
Nat Commun; 2015 Sep; 6():8266. PubMed ID: 26365427
[TBL] [Abstract][Full Text] [Related]
9. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
10. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
11. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
12. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
13. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
14. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
15. Role of Thalidomide on the Expression of OX40, 4-1BB, and GITR in T Cell Subsets.
Kim BS; Kim JY; Kim EJ; Lee JG; Joo DJ; Huh KH; Kim MS; Kim YS
Transplant Proc; 2016 May; 48(4):1270-4. PubMed ID: 27320601
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Treg cells/T effector function by GITR signaling is context-dependent.
Ephrem A; Epstein AL; Stephens GL; Thornton AM; Glass D; Shevach EM
Eur J Immunol; 2013 Sep; 43(9):2421-9. PubMed ID: 23722868
[TBL] [Abstract][Full Text] [Related]
17. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
18. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
19. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L.
Calmels B; Paul S; Futin N; Ledoux C; Stoeckel F; Acres B
Cancer Gene Ther; 2005 Feb; 12(2):198-205. PubMed ID: 15472713
[TBL] [Abstract][Full Text] [Related]
20. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
